15 research outputs found

    Erratum to: 36th International Symposium on Intensive Care and Emergency Medicine

    Get PDF
    [This corrects the article DOI: 10.1186/s13054-016-1208-6.]

    A922 Sequential measurement of 1 hour creatinine clearance (1-CRCL) in critically ill patients at risk of acute kidney injury (AKI)

    Get PDF
    Meeting abstrac

    Sodium dysbalances in neurointensive care: results of a 5-year prospective study

    No full text

    The use of statistical point processes in geoinformation analysis

    No full text
    Many objects in space can best be modeled statistically by using point processes. Examples are fires in an urban environment, herds of animals in large areas, earthquakes and forest fires and large speckles on a radar image. Modern developments in point process theory now much better than before allow us to make statistical models to explain the observed patterns. In this paper, we will address the way that point processes can be modeled in space and time. The first application draws from domestic fires at the city level, where we apply a statistical point pattern analysis to derive major causes from related layers of information. The second application considers earthquakes as a marked point process. For earthquakes, large and complex data sets exist including many possibly relevant covariates that may influence their occurrence. The Strauss point process model is explored to analyze earthquake data in Pakistan recorded since 1973, in particular the major earthquake event occurring in 2005. The model, despite some limitations, is rigorous for applying it to such a marked point pattern, representing well the clustering behaviour as determined by a number of environmental factors. Finally, the Strauss point process model is suggested for the use in identifying and explaining the occurrences of speckles in a radar image

    Orodispersible minitablets of enalapril for use in children with heart failure (LENA): Rationale and protocol for a multicentre pharmacokinetic bridging study and follow-up safety study

    Get PDF
    Introduction: Treatment of paediatric heart failure is based on paradigms extensively tested in the adult population assuming similar underlying pathophysiological mechanisms. Angiotensin converting enzyme inhibitors (ACEI) like enalapril are one of the cornerstones of treatment and commonly used off-label in children. Dose recommendations have been extrapolated from adult experience, but the relationship between dose and pharmacokinetics (PK) in (young) children is insufficiently studied. Furthermore, appropriate paediatric formulations are lacking. Within the European collaborative project LENA, a novel formulation of enalapril orodispersible minitablets (ODMT), suitable for paediatric administration, will be tested in (young) children with heart failure due to either dilated cardiomyopathy or congenital heart disease in two pharmacokinetic bridging studies. Paediatric PK data of enalapril and its active metabolite enalaprilat will be obtained. In a follow-up study, the safety of enalapril ODMTs will be demonstrated in patients on long-term treatment of up to 10 months. Furthermore, additional information about pharmacodynamics (PD) and ODMT acceptability will be collected in all three studies. Methods and Analysis: Phase II/III, open-label, multicentre study. Children with dilated cardiomyopathy (DCM) (n=25; 1 month to less than 12 years) or congenital heart disease (CHD) (n=60; 0 to less than 6 years) requiring or already on ACEI will be included. Exclusion criteria include severe heart failure precluding ACEI use, hypotension, renal impairment, hypersensitivity to ACEI. For those naive to ACEI up-titration to an optimal dose will be performed, those already on ACEI will be switched to an expected equivalent dose of enalapril ODMT and optimised. In the first 8 weeks of treatment, a PK profile will be obtained at the first dose (ACEI naive patients) or when an optimal dose is reached. Furthermore, population PK will be done with concentrations detected over the whole treatment period. PD and safety data will be obtained at least at 2-weeks intervals. Subsequently, an intended number of 85 patients will be followed-up up to 10 months to demonstrate long-term safety, based on the occurrence of (severe) adverse events and monitoring of vital signs and renal function. Ethics and dissemination: Clinical Trial Authorisation and a favourable ethics committee opinion were obtained in all five participating countries. Results of the studies will be submitted for publication in a peer-reviewed journal. Trial registration numbers: EudraCT 2015-002335-17, EudraCT 2015-002396-18, EudraCT 2015-002397-21

    36th International Symposium on Intensive Care and Emergency Medicine : Brussels, Belgium. 15-18 March 2016.

    Get PDF
    corecore